Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes - XML Representation

Raw xml | Download


<Evidence xmlns="http://hl7.org/fhir">
  <id value="236967"/>
  <meta>
    <versionId value="63"/>
    <lastUpdated value="2024-12-14T08:46:28.847Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Evidence 236967</b></p><a name="236967"> </a><a name="hc236967"> </a><a name="236967-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 63; Last updated: 2024-12-14 08:46:28+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-comparator-only-evidence.html">ComparatorOnlyEvidence</a></p></div><p><b>url</b>: <a href="https://fevir.net/resources/Evidence/236967">https://fevir.net/resources/Evidence/236967</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/236967, outcomeId/313960, picoId/85798, sectionId/73215</p><p><b>name</b>: End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960</p><p><b>title</b>: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ComparatorOnlyEvidence}">ComparatorOnlyEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><h3>RelatedArtifacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style="display: none">*</td><td>Part Of</td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><p><b>note</b>: Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR &gt; 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/).</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes -- GLP-1 RA</p>
</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="Group-236948.html">GLP-1 RA Group in Adults with type 2 diabetes</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>End-stage kidney disease</p>
</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href="EvidenceVariable-236965.html">End-stage kidney disease</a></p></blockquote><p><b>synthesisType</b>: <span title="Codes:">NOTSET</span></p><p><b>studyDesign</b>: <span title="Codes:">NO_STUDY</span></p><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Description</b></td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><div><p>Risk 11.9%</p>
</div></td><td><span title="Codes:{http://terminology.hl7.org/CodeSystem/statistic-type C44256}">Proportion</span></td><td>0.119</td></tr></table></div>
  </text>
  <url value="https://fevir.net/resources/Evidence/236967"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/236967"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="outcomeId"/>
    </type>
    <system value="https://app.magicapp.org/#/guidelines"/>
    <value value="313960"/>
  </identifier>
  <identifier>
    <type>
      <text value="picoId"/>
    </type>
    <system value="https://app.magicapp.org/#/guidelines"/>
    <value value="85798"/>
  </identifier>
  <identifier>
    <type>
      <text value="sectionId"/>
    </type>
    <system value="https://app.magicapp.org/#/guidelines"/>
    <value value="73215"/>
  </identifier>
  <name
        value="End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960"/>
  <title
         value="MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <author>
    <name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
  </author>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ComparatorOnlyEvidence"/>
        <display value="ComparatorOnlyEvidence"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <relatedArtifact>
    <type value="part-of"/>
    <resourceReference>
      <type value="Composition"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-conversion-report"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display
               value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
    </resourceReference>
  </relatedArtifact>
  <description
               value="This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <note>
    <text
          value="Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR &gt; 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/)."/>
  </note>
  <variableDefinition>
    <description value="Adults with type 2 diabetes -- GLP-1 RA"/>
    <variableRole value="population"/>
    <observed>🔗 
      <reference value="Group/236948"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value
               value="MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-comparator-85394-C-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="GLP-1 RA Group in Adults with type 2 diabetes"/>
    </observed>
  </variableDefinition>
  <variableDefinition>
    <description value="End-stage kidney disease"/>
    <variableRole value="outcome"/>
    <observed>🔗 
      <reference value="EvidenceVariable/236965"/>
      <type value="EvidenceVariable"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-313960"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="End-stage kidney disease"/>
    </observed>
  </variableDefinition>
  <synthesisType>
    <text value="NOTSET"/>
  </synthesisType>
  <studyDesign>
    <text value="NO_STUDY"/>
  </studyDesign>
  <statistic>
    <description value="Risk 11.9%"/>
    <statisticType>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/statistic-type"/>
        <version value="5.0.0-cibuild"/>
        <code value="C44256"/>
        <display value="Proportion"/>
      </coding>
    </statisticType>
    <quantity>
      <value value="0.119"/>
    </quantity>
  </statistic>
</Evidence>